What is claimed is:

- A substantially purified human DnaJ-like-protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
- An isolated and purified polynucleotide sequence encoding the human DnaJ-2. like protein of claim 1 or fragments or variants of said polynucleotide sequence.
 - A composition comprising the polynucleotide sequence of claim 2.
- A polynucleotide sequence which hybridizes under stringent conditions to the 4. polynucleotide sequence of claim 2.
- A polynucleotide sequence which is complementary to the polynucleotide 5. sequence of claim 2 or fragments or variants thereof.
- An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or 6. fragments or variants thereof.
 - 7. A composition comprising the polynucleotide sequence of claim 6.
- A polynucleotide sequence which is complementary to the polynucleotide 8. sequence of claim 6.
- An expression vector containing at least a fragment of the polynucleotide 9. 25 sequence of claim 2.
 - 10. A host cell containing the vector of claim 9.
- 30 11. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment thereof, the method comprising the steps of:

15

10

The state state

- a) culturing the host cell of claim 10 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
- DnaJ-like protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
 - 13. A purified antibody which specifically binds to the polypeptide of claim 1.
 - 14. A purified agonist which modulates the activity of the polypeptide of claim 1.
 - 15. A purified antagonist which decreases the effect of the polypeptide of claim 1.
 - 16. A pharmaceutical composition comprising the antagonist of claim 14 in conjunction with a suitable pharmaceutical carrier.
 - 17. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 16.
 - 18. A method for treating an immune disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 16.
- 25 19. A method for treating or preventing tissue damage comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.
- 20. A method for detecting a polynucleotide which encodes human DnaJ-like protein in a biological sample comprising the steps of:

5

10

aline the final second tent that

== 15

13

100 A 100

12

- b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human DnaJ-like protein in said biological sample.
- 21. The method of claim 20 wherein the nucleic acid material is amplified by the polymerase chain reaction.
- 22. A substantially purified human DnaJ-like-protein comprising the amino acid sequence of SEQ ID NO:3 or fragments thereof.
- 23. An isolated and purified polynucleotide sequence encoding the human DnaJlike protein of claim 22 or fragments or variants of said polynucleotide sequence.
 - 24. A composition comprising the polynucleotide sequence of claim 23.
- 25. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 23.
- 26. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 23 or fragments or variants thereof
- 27. An isolated and purified polynucleotide sequence comprising SEQ ID NO:4 or fragments or variants thereof.
 - 28. A composition comprising the polynucleotide sequence of claim 26.
- 29. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 27.

- 30. An expression vector containing at least a fragment of the polynucleotide sequence of claim 23.
 - 31. A host cell containing the vector of claim 30.
- 32. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment thereof, the method comprising the steps of:
 - a) culturing the host cell of claim 31 under conditions suitable for the expression of the polypeptide and
 - b) recovering the polypeptide from the host cell culture.
- 33. A pharmaceutical composition comprising a substantially purified human DnaJ-like protein having the amino acid sequence of SEQ ID NO:3 in conjunction with a suitable pharmaceutical carrier.
 - 34. A purified antibody which specifically binds to the polypeptide of claim 22.
 - 35. A purified agonist which modulates the activity of the polypeptide of claim 22.
- 20 36. A purified antagonist which decreases the effect of the polypeptide of claim 22.
 - 37. A pharmaceutical composition comprising the antagonist of claim 35 in conjunction with a suitable pharmaceutical carrier.
 - 38. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 37.
- 39. A method for treating an immune disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 38.

##

ļ. ±

[]

4.4 4.4 4.4 4.4 4.3 4.4 5

15

- 40. A method for treating or preventing tissue damage comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 33.
- 41. A method for detecting a polynucleotide which encodes human DnaJ-like protein in a biological sample comprising the steps of:
 - a) hybridizing the polynucleotide of claim 29 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
 - b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human DnaJ-like protein in said biological sample.
 - 42. The method of claim 20 wherein the nucleic acid material is amplified by the polymerase chain reaction.

15

5

10

20